Cancer is, at its core,
an information problem.

From the classification of mutations and biomarkers within a single tumor cell to the population-wide patterns that inform clinical trials and public health strategies, cancer care has historically advanced in proportion to the volume of available data.

From Virchow's 1858 insight that disease originates within the cell, to The Cancer Genome Atlas, which molecularly characterized over 20,000 tumor samples across 33 cancer types, we have moved from crude organ-level classifications to histological subtypes and their respective genetic signatures. Along this trajectory, we have shifted from highly toxic chemotherapies designed to kill every dividing cell, often with devastating side effects, to highly personalized interventions like neoantigen vaccines now showing promising results in clinical trials.

Today, oncology is moving from one-size-fits-all toward true precision. A paradigm that recognizes each person's unique biological makeup, leveraging computational tools to make sense of extraordinarily complex multi-omics data, and that can anticipate, prevent, and improve outcomes for every patient.

This future is possible, yet not accessible to all.

The genetic variant databases, the AI models predicting treatment response, and even the real-world evidence studies that inform clinical decisions are heavily biased toward populations that look very different from those in Latin America. At a certain level of granularity, each cancer is as unique as the populations it affects. In Mexico, triple-negative breast cancer tends to appear in younger women with a particularly aggressive clinical course. Indigenous American ancestry has been linked to a protective haplotype that reduces the overall risk of breast cancer, yet correlates with a higher frequency of aggressive subtypes when the disease does occur. In Chile, Mapuche ancestry is associated with increased risk of gallbladder cancer, while Aymara ancestry is associated with lower risk, a signal that vanishes entirely when both are collapsed into the generic label of "Indigenous." Biological signals like these, invisible in homogeneous populations, become significant in Latin America. With over 800 Indigenous peoples and a long history of admixture unlike anywhere else in the world, the region is fertile ground for scientific discovery with global implications.

In Mexico, the National Cancer Institute (INCan) sustains more than 15 basic cancer research groups, producing hundreds of internationally cited publications on a fraction of the budget available to counterparts in the United States or Europe. In Colombia, the GLORIA network connects rural pathologists with urban reference centers using telepathology and AI to overcome their severe shortage of specialists. In Peru, the MABIS project brings early breast cancer diagnosis to the most remote reaches of their highlands and jungle. Each of these efforts born from constraint and resolve.

The problem in Latin America is not a lack of innovation, but an issue of fragmentation. A cohort here, a program there, a genetic finding buried in a local journal, often published out of a doctor's own pocket. As long as these efforts stay siloed, we will default to clinical models built on foreign data that do not reflect our social and biological reality. More than an administrative obstacle, this gap represents a profound scientific and human loss. We are squandering the potential of our own clinical legacy, condemning patients to imprecise diagnoses and standardized treatments that overlook their social and biological particularity. This is an equity gap we can no longer afford to ignore.

Omica is here to break this cycle. We are building the scientific foundation for a new era of cancer care, one where the vast, untapped data of Latin America becomes an engine for global scientific breakthroughs. By integrating the region's data, from the molecular level to the population-scale, we can reclaim our narrative and deliver the innovations that our patients deserve.